Thymosin Beta 4 Cuts Heart Damage After Heart Attacks in Mice and Humans
Recombinant human thymosin beta 4 reduces infarct size and cardiac dysfunction via ErbB2 signaling in both animal models and a clinical trial.
Summary
Researchers tested recombinant human thymosin beta 4 (rhTB4) as a cardioprotective therapy after heart attacks. In mice, a 7-day course of rhTB4 following ischemia/reperfusion injury prevented cardiac dysfunction, reduced fibrosis, and lowered biomarkers of heart failure at 28 days. Mechanistically, rhTB4 activated the ErbB2/Raf1 signaling pathway, reducing cardiomyocyte apoptosis. In a small randomized controlled trial of 96 STEMI patients treated with primary PCI, patients receiving rhTB4 within 8 hours post-procedure showed significantly reduced infarct size at 90 days compared to placebo — though the overall group difference did not reach statistical significance, suggesting early administration timing may be critical.
Detailed Summary
Heart attacks — even when treated promptly with modern interventional techniques like percutaneous coronary intervention (PCI) — frequently leave lasting cardiac dysfunction due to ischemia/reperfusion (I/R) injury. Finding agents that protect heart muscle during this critical window remains a major clinical priority, especially for longevity-minded patients and physicians focused on preserving cardiovascular health long-term.
This study investigated recombinant human thymosin beta 4 (rhTB4), a synthetic version of a naturally occurring peptide with known roles in tissue repair and cytoprotection. Researchers used two mouse models — an I/R model and a permanent ligation model — to assess rhTB4's impact on cardiac function, fibrosis, and infarct size over 4–8 weeks. They also conducted RNA sequencing to identify mechanistic pathways.
In both mouse models, rhTB4 treatment significantly preserved cardiac function, reduced fibrosis, and shrank infarct size. RNA-seq and in vitro experiments pinpointed the ErbB2/Raf1 signaling pathway as a key mediator; blocking ErbB2 abolished rhTB4's cardioprotective effects. The peptide also suppressed the pro-apoptotic protein Bad, reducing cardiomyocyte death under hypoxic stress.
The clinical arm was a randomized, double-blind, placebo-controlled trial in 96 STEMI patients. Patients receiving rhTB4 within 8 hours of PCI (n=43) showed meaningfully reduced infarct areas at 90 days — but the overall between-group comparison across all 96 patients was not statistically significant, likely due to variable timing of administration.
The findings are promising but preliminary. The small trial size and the timing-dependent effect suggest larger, better-powered trials with strict early-administration protocols are needed before rhTB4 can be considered a standard adjunct to PCI in heart attack care.
Key Findings
- 7-day rhTB4 treatment prevented cardiac dysfunction and fibrosis 28 days post-I/R in mice.
- rhTB4 activates ErbB2/Raf1 signaling, reducing cardiomyocyte apoptosis and Bad protein expression.
- ErbB2 inhibition completely abolished rhTB4's cardioprotective effects in mouse models.
- STEMI patients receiving rhTB4 within 8 hours of PCI had significantly reduced infarct size at 90 days.
- Overall clinical trial group difference was not statistically significant across all 96 patients.
Methodology
Study used two murine cardiac injury models (I/R and permanent ligation) with RNA-seq pathway analysis and in vitro hypoxia/reoxygenation assays. Clinical component was a randomized, double-blind, placebo-controlled trial in 96 STEMI patients across multiple Chinese centers. Cardiac MRI was used to assess infarct size at 90-day follow-up.
Study Limitations
The clinical trial was underpowered (n=96) and did not achieve overall statistical significance, limiting conclusions. Subgroup benefit (early dosing within 8 hours) introduces potential selection bias. Conflict of interest exists as some authors are employees of the company producing rhTB4.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.